Schmidt-Hieber, Martin <br/><br/>
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.  [electronic resource] 

 -  Investigational new drugs  Apr 2012 
 - 480-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-0646 
<br/><br/><label>Standard No.: </label>10.1007/s10637-010-9576-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis--drug effects<br/>Boronic Acids--pharmacology<br/>Bortezomib<br/>Caspase 3--metabolism<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Dose-Response Relationship, Drug<br/>Drug Synergism<br/>Flow Cytometry<br/>HL-60 Cells<br/>Humans<br/>Immunohistochemistry<br/>Inhibitory Concentration 50<br/>K562 Cells<br/>Ki-67 Antigen--metabolism<br/>Lenalidomide<br/>Leukemia, Myeloid--metabolism<br/>Lymphoma--metabolism<br/>Multiple Myeloma--metabolism<br/>Phosphorylcholine--analogs & derivatives<br/>Pyrazines--pharmacology<br/>Thalidomide--analogs & derivatives<br/>Time Factors